Wockhardt: Biotech Growth & Pharma Recovery Ahead

Wockhardt is showing a meaningful earnings recovery, with Q1 FY27 consolidated revenue rising 26% YoY to ₹929 crore and PAT turning positive at ₹107 crore versus a ₹108 crore loss in Q1 FY26. EBITDA increased 86% YoY, while biotech revenue surged 112% to ₹236 crore, highlighting strong momentum in the higher-value business.  Latest News: India branded business grew 21% to ₹156 crore, supported by diabetes therapy, Emrok and regenerative dermatology. Wockhardt also secured multiple international approvals and launched new products, strengthening its global pipeline. Corporate Action/Catalysts: FY26 EBITDA increased 51% to ₹630 crore, while the company raised ₹1,000 crore through a QIP, providing capital for growth investments. Upcoming insulin-analogue launches could become a major catalyst. Key risks remain regulatory compliance, execution, R&D spending and the sustainability of the recent earnings turnaround.